Vanessa, in partnership with her colleague, Dr. Anderson, served as the U.S. D&I leads for the Employee Resource Group (ERG) Capitol Hill Fly-In. They worked to produce content, align with ERG associates for the opportunity and partnered with Public Affairs to execute the initiative. The Fly-in provided Novartis associates who participate in ERGs with an
Meet our 2021 Employee Champions. We recognize individuals who strive to advance science and support innovation so that patients around the world can get the medicines and treatments they need. This year’s recipients have demonstrated commitment and resiliency that goes above and beyond expectations.
Dr. Anderson, in partnership with her colleague, Vanessa Adams, served as the U.S. D&I leads for the Employee Resource Group (ERG) Capitol Hill Fly-In. They worked to produce content, align with ERG associates for the opportunity and partnered with Public Affairs to execute the initiative. The Fly-in provided Novartis associates who participate in ERGs with
With years of experience in both pharmaceuticals and digital medicine, Rohit is driving Otsuka’s launch strategy to bring prescription digital therapeutics to patients suffering from serious mental illness. His work has propelled Otsuka as a driver of legislation around creating a benefit category and reimbursement paradigm for PDTs.
Saloni’s work brought the first-ever approved treatment to address symptoms of agitation associated with dementia due to Alzheimer’s disease. She has also engaged with members of Congress and administration staff to help drive awareness of the disease. Additionally, she has advocated for policy changes that are reflective of the evolving treatment landscape.
Over the years, Dr. Chureen Carter has demonstrated her commitment to supporting and mentoring rising scientists. In her work building alliances that support evidence generation, Dr. Carter puts patients first, ensuring stakeholders understand the full value of the medicines they need. She has an exceptional ability to build bridges, whether with partners outside the organization
A self-described “number monkey,” Doug’s work in data modeling has been an essential component of Merck’s legislative strategy. Doug is committed to ensuring the government affairs team is always equipped with data to guide and advance their advocacy efforts. His recent work on drug pricing reform echoes his ability to supply complex guidance in a
In 2020, Dr. Dent was a key voice in discussing the importance of biomarkers for Alzheimer’s disease with members of Congress. She participated in Capitol Hill briefings and attended multiple meetings with legislators to explain the issue. She is a powerful advocate for pioneering innovation and continues to be a trusted advisor and partner to
As a specialist in cell therapy, Victoria has played a vital role in engaging policymakers at every level of government including state and federal “fly-ins” hosted by PhRMA. BMS’s Policy, Government Affairs, and Advocacy team is continually impressed by her thoughtful approach to educating and advocating for medical innovation, like CAR T.
Kim is an individual who is committed to helping educate policymakers and stakeholders about the important and challenging work of developing new medicines for patients. She participates in several fly-ins and she’s UCB’s leading voice on the importance of diversity in clinical trials and is leading work to advance the company in this area. Her
Marci has raised awareness of women’s health needs and research efforts at Astellas to treat them. She has discussed the stigma around talking about menopause and other aspects of women’s health. At the same time, Marci joined researchers from companies around the country to meet with members of Congress and their staff to discuss their